Search Results - Kerstin Allen
- Showing 1 - 7 results of 7
-
1
a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL by Ian W. Flinn, Yasuhiro Oki, Manish R. Patel, Steven M. Horwitz, Francine M. Foss, Jennifer Sweeney, Kerstin Allen, Mark Douglas, Lori Steelman, Joi Dunbar, Howard M. Stern, Patrick Kelly, Brad S. Kahl
Published 2014Artigo -
2
Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder by Sean J. Pittock, Michael Barnett, Jeffrey L. Bennett, Achim Berthele, de Sèze, Michael Levy, Ichiro Nakashima, Celia Oreja‐Guevara, Jacqueline Palace, Friedemann Paul, Carlo Pozzilli, Marcus Yountz, Kerstin Allen, Yasmin Mashhoon, Ho Jin Kim
Published 2023Artigo -
3
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies by Ian W. Flinn, Susan O’Brien, Brad S. Kahl, Manish R. Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Virginia Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz
Published 2017Artigo -
4
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study by Susan O’Brien, Manish R. Patel, Brad S. Kahl, Steven M. Horwitz, Francine M. Foss, Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Kerstin Allen, L. Kerrie, Mark Douglas, Howard M. Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Ian W. Flinn
Published 2018Artigo -
5
Survival Data and Predictors of Functional Outcome an Average of 15 Years after the Fontan Procedure: The Pediatric Heart Network Fontan Cohort by Andrew M. Atz, Victor Zak, Lynn Mahony, Karen Uzark, Peter Shrader, Dianne Gallagher, Stephen M. Paridon, Richard V. Williams, Roger E. Breitbart, Steven D. Colan, Jonathan R. Kaltman, Renée Margossian, Sara K. Pasquali, Kerstin Allen, Wyman W. Lai, Rosalind Korsin, Bradley S. Marino, Nicole Mirarchi, Brian W. McCrindle
Published 2014Artigo -
6
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma by Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison J. Moskowitz, Megan N. Perez, Patricia L. Myskowski, Adam Officer, Jacob D. Jaffe, Sara Morrow, Kerstin Allen, Mark Douglas, Howard M. Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C. Aster, David T. Weaver, Francine M. Foss, David M. Weinstock
Published 2017Artigo -
7
Interstage mortality after the Norwood procedure: Results of the multicenter Single Ventricle Reconstruction trial by Nancy S. Ghanayem, Kerstin Allen, Sarah Tabbutt, Andrew M. Atz, Martha L. Clabby, David S. Cooper, Pirooz Eghtesady, Peter C. Frommelt, Peter J. Gruber, Kevin D. Hill, Jonathan R. Kaltman, Peter C. Laussen, Alan B. Lewis, Karen J. Lurito, L. LuAnn Minich, Richard G. Ohye, Julie V. Schonbeck, Steven M. Schwartz, Rakesh K. Singh, Caren S. Goldberg
Published 2012Artigo
Search Tools:
Related Subjects
Internal medicine
Medicine
Adverse effect
Gastroenterology
Lymphoma
Pharmacodynamics
Pharmacokinetics
Cardiology
Chronic lymphocytic leukemia
Clinical trial
Febrile neutropenia
Heart disease
Immunology
Leukemia
Neutropenia
Oncology
Pediatrics
Phases of clinical research
Alternative medicine
Anemia
Antibody
Astrobiology
Biology
Biotechnology
Cancer research
Chemotherapy
Clinical endpoint
Cmax
Cohort
Complement system